HMN 2026: How Stopping weight loss drugs is linked to weight regain and reversal of heart health markers

Stopping weight loss drugs is followed by weight regain and reversal of beneficial effects on heart and metabolic health markers such as high cholesterol and high blood pressure, finds a study published in The BMJ.

The study shows that the average rate of weight regain is 0.4kg/month after stopping treatment, with weight and risk markers for diabetes and heart disease predicted to return to pre-treatment levels in less than two years. It also finds that the rate of weight regain after stopping weight loss drugs is almost four times faster than after diet and physical activity changes, irrespective of the amount of weight lost during treatment.

“This evidence suggests that despite their success in achieving initial weight loss, these drugs alone may not be sufficient for long term weight control,” say the researchers.

How the study was conducted

The development of highly effective weight management medications such as glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide and tirzepatide, has transformed the treatment of obesity. Yet it is estimated that around half of people with obesity discontinue GLP-1 drugs within 12 months, so it’s important to understand what happens to body weight and risk markers for conditions like diabetes and heart disease after stopping treatment.

To do this, a team of researchers from the University of Oxford searched registries and databases for trials and observational studies that compared the effects of any medication licensed for weight loss in adults with any non-drug weight loss intervention (behavioral weight management programs) or placebo.

The studies were designed differently and varied in quality, but the researchers were able to assess their risk of bias using established tools.

Key findings and limitations

Thirty-seven studies published up to February 2025, involving 9,341 participants, were included in the analysis. The average duration of weight loss treatment was 39 weeks, with an average follow-up of 32 weeks.

Participants treated with weight loss drugs regained on average 0.4 kg/month after stopping treatment and were projected to return to their pre-treatment weight by 1.7 years. All cardiometabolic risk markers were projected to return to pre-treatment levels within 1.4 years after stopping the drugs.

Monthly weight regain was also faster after weight loss drugs than after behavioral weight management programs (by 0.3 kg), independent of initial weight loss.

The authors acknowledge several limitations. For example, only eight studies assessed treatment with the newer GLP-1 drugs and the maximum follow-up period in these studies was 12 months after medication stopped. Moreover, few studies were at low risk of bias.

Nevertheless, the researchers point out that they used three methods of analysis and all provided similar results, adding certainty to their findings.

Implications for obesity treatment

As such, they conclude, “This evidence cautions against short-term use of weight management medications, emphasizes the need for further research into cost-effective strategies for long-term weight control, and reinforces the importance of primary prevention.”

“The study findings cast doubt on the notion that GLP-1 receptor agonists are a perfect cure for obesity,” says a US researcher in a linked editorial.

“People taking GLP-1 receptor agonists should be aware of the high discontinuation rate and the consequences of cessation of medications,” he writes. “Healthy dietary and lifestyle practices should remain the foundation for obesity treatment and management, with medications such as GLP-1 receptor agonists used as adjuncts.”

“Such practices not only help prevent excess weight gain but can also lead to numerous health benefits that go beyond weight control,” concludes the researcher.

The content is provided for information purposes only.